Search MalaCards:
MCID: SCN007

Secondary Hyperparathyroidism malady
5 drugs, 59 genes, 3 tissues, 756 related diseases, 26 phenotypes, 150 articles, clinical trials.

Summaries for Secondary Hyperparathyroidism

about this section
Sources:
44Wikipedia, 22MalaCards
See all sources

Export this MalaCard
Wikipedia: Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone (PTH) by the...44 more...

MalaCards: Secondary Hyperparathyroidism, also known as secondary hyperparathyroidism (disorder), is related to hyperparathyroidism-jaw tumor syndrome and familial isolated hyperparathyroidism. An important gene associated with Secondary Hyperparathyroidism is NR1I3 (nuclear receptor subfamily 1, group I, member 3), and among its related pathways are Actin-Based Motility by Rho Family GTPases and Development_Hedgehog and PTH signaling pathways in bone and cartilage development. The drugs calcitriol and dihydrotachysterol and the compounds 25-hydroxyvitamin d and titanium have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and b cells, and related mouse phenotypes are craniofacial and respiratory system.

Aliases & Descriptions for Secondary Hyperparathyroidism

about this section
Sources:
43UMLS, 6Disease Ontology, 32Novoseek , 24MeSH, 40SNOMED-CT
See all sources

Aliases & Descriptions:

secondary hyperparathyroidism 6
secondary hyperparathyroidism (disorder) 6
secondary hyperparathyroidism nos 6
hyperparathyroidism, secondary 43
hyperparathyroidism secondary 32
hyperparathyroidism 43

External Ids:

SNOMED-CT40 91478007

Related Diseases for Secondary Hyperparathyroidism

about this section
Sources:
13GeneCards, 14GeneDecks
See all sources

Diseases related to secondary hyperparathyroidism by text searches and GeneDecks gene sharing:

(show top 50)    (show all 753)
idRelated DiseaseScoreTop Affiliating Genes
1hyperparathyroidism-jaw tumor syndrome35.4CDC73, CASR
2familial isolated hyperparathyroidism34.2RET, CDC73, MEN1, CASR, PTH, GAST
3hyperparathyroidism, neonatal severe primary31.1CASR, NR1I3, CXADR
4parathyroid carcinoma30.9CDC73, MEN1, CASR, PTH, CXADR
5hypocalciuric hypercalcemia30.8CASR, CALCA, PTH, SPG7, NR1I3, CXADR
6osteitis fibrosa30.2BGLAP, B2M, ALPP, CASR, CALCA, PTH
7familial hypocalciuric hypercalcemia30.0CASR, SPG7, NR1I3, CXADR
8secondary hyperparathyroidism of renal origin29.6VDR, BMP7, BGLAP, B2M, CD36, FGF23
9humoral hypercalcemia of malignancy29.2BGLAP, FGF23, CASR, PTH1R, NR1I3
10nephrocalcinosis29.0ALB, CASR, NR1I3, SLC34A1
11osteomalacia28.5KL, GC, VDR, BGLAP, CD36, FGF23
12multiple endocrine neoplasia type 2a28.5RET, CDC73, MEN1, CALCA, PTH
13hypocalcemia28.3VDR, BGLAP, CD36, FGF23, ALB, ALPP
14osteosclerosis27.7BGLAP, ALPP, TNFRSF11B, PTH, PDLIM3
15clear cell adenoma27.7ALPP, PTH
16ossifying fibroma27.6BGLAP, CDC73, RUNX2
17multiple endocrine neoplasia27.4RET, VIP, CHGA, CDKN1A, CDKN2C, CDC73
18parathyroid disorders27.2RET, CDC73, MEN1, CASR, PTH
19primary hyperparathyroidism27.0RET, VDR, BGLAP, PAX5, CHGA, CD36
20parathyroid adenoma26.6RET, VIP, VDR, BGLAP, CHGA, CDKN2C
21liver cirrhosis26.4VIP, GPT, IGFBP3, ALB, ALPP, TNFRSF11B
22papillary thyroid carcinoma26.4RET, FGFR1, MEN1, CCND1, CALCA, CTNNB1
23breast cancer26.3CDKN1B, CCND1, GHR, CTNNB1, EGFR, TGFA
24fibrous dysplasia26.3BGLAP, CD36, FGF23, IL6, ALPP, CALCA
25rickets26.1GC, VDR, BGLAP, CD36, INS, FGF23
26renal osteodystrophy26.1VDR, BMP7, BGLAP, B2M, CD36, FGF23
27thymoma25.9VIP, CHGA, B2M, CDKN1A, CALCA, GHR
28mccune albright syndrome25.8BGLAP, FGF23, MEN1, IGFBP3, IGF1, ALPP
29obesity, association with25.6INS, IL6, GPT, IGF1, ALB, CASR
30peptic ulcer25.3FGF2, MEN1, IL6, CCK, ALB, GHRL
31mediastinitis25.3PAX5, IL6, ALPP, CALCA, PTH, EGFR
32goiter25.2RET, BGLAP, INS, FGFR1, IGFBP3, IGF1
33hypoparathyroidism25.0RET, VDR, BGLAP, INS, FGF23, IGF1
34amyloidosis24.8RET, BGLAP, B2M, INS, IL6, CCND1
35hemangioma24.7RET, CHGA, FGF2, MEN1, CALCA, CTNNB1
36hypercalcemia24.6KL, GC, VDR, BGLAP, CHGA, B2M
37arterial calcification24.6GC, VDR, BGLAP, CD36, INS, FGF23
38insulinoma24.5VIP, CHGA, CDKN1A, CDKN1B, INS, MEN1
39anemia24.2VDR, BMP7, CHGA, B2M, CDKN1A, CDKN1B
40papilloma24.1RET, CDKN1A, CD36, CDKN1B, MEN1, CCND1
41neurofibromatosis23.9RET, CHGA, B2M, MEN1, IL6, IGFBP3
42hyperparathyroidism23.8KL, RET, GC, VIP, VDR, BMP7
43uremia23.2RET, VIP, VDR, CHGA, B2M, INS
44osteoporosis23.1KL, GC, VDR, BMP7, BGLAP, PAX5
45pheochromocytoma23.1RET, VIP, CHGA, CDKN2C, CD36, CDKN1B
46thyroid cancer22.8RET, BGLAP, CHGA, B2M, CDKN1A, CDKN1B
47glomerulonephritis22.5BGLAP, B2M, CD36, INS, FGF2, IL6
48thyroid carcinoma22.5RET, VDR, BGLAP, CDKN1A, CD36, CDKN1B
49sickle cell disease22.4KL, BGLAP, B2M, CD36, INS, IL6
50aldosteronism21.7KL, VIP, BMP7, CHGA, B2M, CD36

Graphical network of the top 20 diseases related to secondary hyperparathyroidism:



Graphical network of diseases related to secondary hyperparathyroidism

Clinical Features for Secondary Hyperparathyroidism

about this section

Drugs & Therapeutics for Secondary Hyperparathyroidism

about this section
Sources:
4CenterWatch, 29NIH Clinical Center, 5ClinicalTrials, 43UMLS, 28NDF-RT
See all sources

Approved drugs:

Search CenterWatch for secondary hyperparathyroidism

Drug clinical trials:

Search ClinicalTrials for secondary hyperparathyroidism

Search NIH Clinical Center for secondary hyperparathyroidism

Search CenterWatch for secondary hyperparathyroidism

Inferred drug relations via UMLS/NDF-RT:

43 28 calcitriol, cod liver oil [va product], dihydrotachysterol, doxercalciferol, paricalcitol

Genetic Tests for Secondary Hyperparathyroidism

about this section

Anatomical Context for Secondary Hyperparathyroidism

about this section
Sources:
22MalaCards
See all sources

MalaCards organs/tissues related to secondary hyperparathyroidism:

22
Kidney, T cells, B cells

Phenotypes for genes affiliated with Secondary Hyperparathyroidism

about this section
Sources:
25MGI
See all sources

MGI Mouse Phenotypes related to secondary hyperparathyroidism:

25 (show all 26)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1craniofacial phenotypeMP:00053829.8RUNX2, PTH1R, PTH, MEN1
2respiratory system phenotypeMP:00053889.4RUNX2, PTH1R, CALCA, FGF23, CDC73, RET
3hematopoietic system phenotypeMP:00053979.0CDKN1A, CDKN2C, CDC73, FGF2, FGF23, CCND1
4endocrine/exocrine gland phenotypeMP:00053799.0RUNX2, PTH, GHR, MEN1, FGFR1, CDKN1B
5limbs/digits/tail phenotypeMP:00053718.2PTH, CTNNB1, EGFR, ACP5, RUNX2, TNFRSF11B
6embryogenesis phenotypeMP:00053808.1CXADR, PRL, EGFR, CTNNB1, PTH1R, ALPP
7hearing/vestibular/ear phenotypeMP:00053777.9EGFR, CTNNB1, TNFRSF11B, CALCA, IGF1, FGFR1
8integument phenotypeMP:00107717.5CALCA, CTNNB1, EGFR, TGFA, PRL, SLC20A1
9reproductive system phenotypeMP:00053897.3BMP7, VDR, VIP, RET, B2M, CDKN2C
10liver/biliary system phenotypeMP:00053707.2EPO, SLC20A1, PRL, EGFR, NR1I3, GHR
11normal phenotypeMP:00028737.0ALB, ALPP, GHRL, PDLIM3, SLC20A1, EPO
12immune system phenotypeMP:00053876.7GAST, RUNX2, PAX5, VDR, KL, CEBPB
13renal/urinary system phenotypeMP:00053676.6SLC34A1, RET, KL, BMP7, CHGA, NPPA
14behavior/neurological phenotypeMP:00053866.4CALCA, GHR, GHRL, SPG7, CTNNB1, PRL
15adipose tissue phenotypeMP:00053756.3IGFBP3, IGF1, GHR, GHRL, EGFR, TGFA
16tumorigenesisMP:00020066.1CCND1, IGF1, CTNNB1, EGFR, PRL, CST3
17nervous system phenotypeMP:00036316.0CCND1, CCK, GHR, SPG7, EGFR, PRL
18vision/eye phenotypeMP:00053915.9CCND1, CASR, CTNNB1, EGFR, TTR, TGFA
19skeleton phenotypeMP:00053905.8CEBPB, BMP7, VDR, GC, CTNNB1, SPG7
20mortality/agingMP:00107685.6PTH, RET, KL, VDR, BMP7, TNFRSF11B
21muscle phenotypeMP:00053695.6CASR, IGF1, IGFBP3, IL6, MEN1, FGFR1
22digestive/alimentary phenotypeMP:00053814.9GAST, RUNX2, CXADR, TGFA, EGFR, CTNNB1
23growth/size phenotypeMP:00053784.5RUNX2, SLC20A1, SLC34A1, TGFA, EGFR, NR1I3
24cellular phenotypeMP:00053844.4TNFRSF11B, CASR, IGF1, IGFBP1, CCND1, CTNNB1
25cardiovascular system phenotypeMP:00053853.5EPO, RUNX2, SLC20A1, NPPA, CST3, CXADR
26homeostasis/metabolism phenotypeMP:00053761.6GAST, EPO, RUNX2, SLC20A1, SLC34A1, SLPI

Publications for genes affiliated with Secondary Hyperparathyroidism

about this section
Sources:
35PubMed
See all sources

Articles related to secondary hyperparathyroidism:

(show top 50)    (show all 150)
idTitleAuthorsYearAffiliating Genes
1L-type voltage-dependent calcium channel alpha subuni t 1C is a novel candidate gene associated with secondary hyperparathyroidism: a n application of haplotype-based analysis for multiple linked single nucleotide polymorphisms. (20424473)Yokoyama K.... Hosoya T.2010SLC6A11
2Fibroblast growth factor-23 in early chronic kidney d isease: additional support in favor of a phosphate-centric paradigm for the pat hogenesis of secondary hyperparathyroidism. (20448073)Evenepoel P.... Vanrenterghem Y.2010FGF23
3Comparison of oral falecalcitriol and intravenous cal citriol in hemodialysis patients with secondary hyperparathyroidism: a randomiz ed, crossover trial. (19473635)Ito H.... Kinugasa E.2009CD36, BGLAP
4Management of secondary hyperparathyroidism in the el derly patient with chronic kidney disease. (19591520)Cozzolino M.... Brancaccio D.2009CASR
5Persistent Secondary Hyperparathyroidism and Vertebra l Fractures in Kidney Transplantation: Role of Calcium-Sensing Receptor Polymor phisms and Vitamin D Deficiency. (19839774)Giannini S.... Bonfante L.2009CASR
6Clinical aspect of recent progress in phosphate meta bolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney dise ase (19483275)Goto S.... Fukagawa M.2009FGF23
7Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidism. (18398016)Martins P.... FrazALo J.M.2008FGF2
8Race is a major determinant of secondary hyperparathyroidism in uremic patients: comparative study of Blacks and Hispanics. (18826856)Omije D.... Gupta A.2008ALB, PAX5
9Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis. (18045826)DA-ez J.J.... Selgas R.2008VIP, CCK, GHRL
10The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. (18178780)Messa P.... Locatelli F.2008CASR
11Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. (18387159)Akiba T.... Koshikawa S.2008CASR, BGLAP
12Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. (18579641)Arcidiacono M.V.... Dusso A.S.2008TGFA
13Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. (17622482)Cibulka R.... Siroka R.2007TNFRSF11B
14Renal transplant and secondary hyperparathyroidism. (18050015)GA... Bergrem H.2007ALB
15Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism. (17498002)Ogata H.... Taguchi S.2007CD36, BGLAP
16Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. (17702720)Kovesdy C.P.... Kalantar-Zadeh K.2007ALB
17Body composition changes in haemodialysis patients wi th secondary hyperparathyroidism after parathyroidectomy measured by convention al and vector bioimpedance analysis. (16469153)Peters B.S.... Martini L.A.2006ALB
18High prevalence of secondary hyperparathyroidism due to hypovitaminosis D in hospitalized elderly with and without hip fracture. (17114912)Giusti A.... Pioli G.2006ALB
19Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. (16291838)Levi R.... Silver J.2006CASR, NR1I3
20Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability. (15882268)Santamaria I.... Cannata-Andia J.B.2005HNRNPD
21FGF-23 in primary and secondary hyperparathyroidisms (16279697)Imanishi Y.... Kobayashi K.2005FGF23
22Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. (16105030)D'Amour P.... Zahradnik R.J.2005PTH
23Cell proliferation of parathyroid gland in patients with progressive secondary hyperparathyroidism: Vitamin D receptor, calcium sensing receptor, and cell cycle regulation factor (16279026)Tokumoto M.... Iida M.2005VDR, CASR
24Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. (15956805)Nishi H.... Fukagawa M.2005FGF23
25Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism. (15728789)Sanchez C.P.... He Y.Z.2005IGF1, BMP7, GHR
26Influence of vitamin D receptor gene polymorphisms on secondary hyperparathyroidism and bone density after kidney transplantation. (15848611)Falkiewicz K.... Patrzal/ek D.2005VDR
27Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism. (15086913)Sanchez C.P.... Wilsman N.J.2004IGF1
28Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. (15264182)Shigematsu T.... Fukagawa M.2004FGF23
29Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients. (15354979)Lin C.L.... Huang C.C.2004EPO
30Cinacalcet for secondary hyperparathyroidism in patie nts receiving hemodialysis. (15071126)Block G.A.... Goodman W.G.2004CASR
31The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. (12595492)Quarles L.D.... Bushinsky D.A.2003CXADR
32Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients. (14606707)Doi S.... Harada S.2003ALPP, ACP5, BGLAP
33Maxacalcitol, a medicine for secondary hyperparathyroidism (2 degrees HPT) (12617040)Imazeki I.2003VDR
34Spermatogenesis after parathyroidectomy in patients w ith symptomatic secondary hyperparathyroidism. (12788420)Chou F.F.... Hsu K.L.2003PRL
35Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27. (12771291)Tokumoto M.... Iida M.2003VDR, CDKN1B, CDKN1A
36Early effects of parathyroidectomy on erythropoietin production in secondary hyperparathyroidism. (11918889)Yasunaga C.... Goya T.2002EPO
37Parathyroid hormone gene polymorphism and secondary hyperparathyroidism in hemodialysis patients. (12046039)Gohda T.... Tomino Y.2002PTH
38Control of the secondary hyperparathyroidism by the suppression of plasma phosphate level in chronic renal failure patients (15775650)Suzuki M.2001VDR
39A clinical study on active vitamin D pulse therapy in hemodialysis patients with secondary hyperparathyroidism (10806572)Ehara H.... Deguchi T.2000ALPP
40Dietary content may prevent secondary hyperparathyroidism in female rhesus monkeys (Macaca mulatta). (10870671)Bruner J.E.... Binkley N.2000SLPI
41The effects of parathyroidectomy on nutritional and biochemical status of hemodialysis patients with severe secondary hyperparathyroidism. (10528050)Khajehdehi P.... Bastani B.1999TF, ALB
42Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. (10095798)Brandi L.... Olgaard K.1998ALB
43Calciotropic hormones and markers of bone remodeling in age-related (type II) femoral neck osteoporosis: alterations consistent with secondary hyperparathyroidism-induced bone resorption. (9310082)Boonen S.... Bouillon R.1997CALCA, GC
44In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. (9011580)Bai M.... Steinmann B.1997NR1I3
45Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. (8883025)Brandi L.... Olgaard K.1996BGLAP
46Secondary hyperparathyroidism in the elderly. Apropos of 200 assays of intact parathormone (7899390)Pfitzenmeyer P.... Gaudet M.1995ALB, TTR
47Age-related bone loss and senile osteoporosis: evidence for both secondary hyperparathyroidism and skeletal growth factor deficiency in the elderly. (8835078)Boonen S.... Dequeker J.1995IGF1
48Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol. (8142673)Shigematsu T.... Sakai O.1993ALPP
49Clinical study of total parathyroidectomy and autotransplantation for secondary hyperparathyroidism (1474716)Mizoguchi H.... Fujiwara T.1992PDLIM3
50Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals. (1947853)Lind L.... Ljunghall S.1991SLPI

Expression for genes affiliated with Secondary Hyperparathyroidism

about this section
Sources:
1BioGPS
See all sources
Expression patterns in normal tissues for genes affiliated with Secondary Hyperparathyroidism

Pathways for genes affiliated with Secondary Hyperparathyroidism

about this section
Sources:
36QIAGEN, 41Thomson Reuters, 10EMD Millipore, 20KEGG
See all sources

Pathways related to secondary hyperparathyroidism according to GeneDecks:

(show top 50)    (show all 71)
idPathwayScoreTop Affiliating Genes
1Actin-Based Motility by Rho Family GTPases3610.3BMP7, FGF23, IGF1
2Development_Hedgehog and PTH signaling pathways in bone and cartilage development4110.0RUNX2, PTH1R, PTH, CCND1, BGLAP, VDR
3Development Hedgehog and PTH signaling pathways in bone and cartilage development1010.0RUNX2, PTH1R, PTH, CCND1, BGLAP, VDR
414-3-3 Induced Intracellular Signaling369.9BMP7, FGF2, FGF23, IGF1
5Breast Cancer Regulation by Stathmin1369.8TGFA, EGFR, FGF23, FGF2, BMP7
6CREB Pathway369.7IGF1, FGFR1, FGF23, BMP7
7Glioblastoma Multiforme369.7EGFR, CDKN1B, CDKN1A
8JNK Pathway369.5IL6, FGFR1, FGF2, CEBPB, BMP7
9Akt Signaling369.4CCND1, IL6, FGFR1, FGF23, BMP7
10Transcription_Role of VDR in regulation of genes involved in osteoporosis419.3VDR, RUNX2, PTH1R, PTH, TNFRSF11B, CALCA
11Transcription Role of VDR in regulation of genes involved in osteoporosis109.3RUNX2, PTH1R, PTH, TNFRSF11B, CALCA, IGF1
12Ras Pathway369.2TGFA, EGFR, FGFR1, FGF23, FGF2, BMP7
13Epithelial Adherens Junctions369.2TGFA, EGFR, CTNNB1, FGFR1, FGF23, FGF2
14Rac1 Pathway369.2IGF1, IL6, FGFR1, FGF23, FGF2, BMP7
15Paxillin Interactions369.2TGFA, EGFR, IGF1, FGFR1, FGF23, FGF2
16ERK5 Signaling369.1TGFA, EGFR, IL6, FGFR1, FGF23, BMP7
17Melanoma208.9EGFR, IGF1, CCND1, FGFR1, FGF23, FGF2
18ILK Signaling368.9TGFA, EGFR, CTNNB1, IGF1, FGFR1, FGF23
19PPAR Pathway368.8EGFR, IGF1, IL6, FGFR1, FGF23, FGF2
20Glioma208.8CDKN1A, CCND1, IGF1, EGFR, TGFA
21Selected targets of GCR-alpha108.7NR1I3, GHR, IGFBP1, IL6, INS, CDKN1A
22Apoptotic Pathways in Synovial Fibroblasts368.6TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
23p53 Mediated Apoptosis368.6TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
24Telomerase Components in Cell Signaling368.6TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
25Mitochondrial Apoptosis368.6TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
26NF-KappaB (p50-p65) Pathway368.5TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
27DHA Signaling368.5TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
28NF-KappaB Family Pathway368.5TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
29Cellular Apoptosis Pathway368.5TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
30Nuclear Receptor Activation by Vitamin-A368.5TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
31Transcription_Androgen Receptor nuclear signaling418.5EGFR, CTNNB1, IGF1, CCND1, IL6, CDKN1A
32Transcription Androgen Receptor nuclear signaling108.5EGFR, CTNNB1, IGF1, CCND1, IL6, CDKN1A
33IP3 Pathway368.4TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
34Activation of PKC through GPCR368.4TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
35Renin-Angiotensin Pathway368.4TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
36Nanog in Mammalian ESC Pluripotency368.4TGFA, EGFR, CTNNB1, IGF1, IL6, FGFR1
37Rap1 Pathway368.3TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
38TGF-Beta Pathway368.3TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
39GSK3 Signaling368.3TGFA, EGFR, CTNNB1, IGF1, IL6, FGFR1
40eNOS Signaling368.2TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
41NFAT in Immune Response368.1TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
42Pathways in cancer208.0TGFA, EGFR, CTNNB1, CCND1, FGFR1, FGF23
43Estrogen Pathway368.0TGFA, EGFR, IGF1, CCND1, IL6, FGFR1
44mTOR Pathway367.8TGFA, IGF1, IL6, FGF23, FGF2, INS
45eIF2 Pathway367.8TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
46p70S6K Signaling367.7TGFA, EGFR, IGF1, IL6, FGFR1, FGF23
47JAK-STAT Pathway367.7EPO, PRL, TGFA, EGFR, GHR, IGF1
48Prostate cancer207.7TGFA, EGFR, CTNNB1, IGF1, CCND1, FGFR1
49Molecular Mechanisms of Cancer367.7TGFA, EGFR, CTNNB1, CCND1, IL6, FGFR1
50Pancreatic Adenocarcinoma367.6IL6, CCND1, IGF1, EGFR, TGFA, FGFR1

Compounds for genes affiliated with Secondary Hyperparathyroidism

about this section
Sources:
32Novoseek , 9DrugBank, 18HMDB, 42Tocris Bioscience, 34PharmGKB
See all sources

Compounds related to secondary hyperparathyroidism according to GeneDecks:

(show top 50)    (show all 368)
idCompoundScoreTop Affiliating Genes
125-hydroxyvitamin d32 10.0SLPI, ACP5, PTH, TNFRSF11B, CASR, ALPP
2titanium32 9.8CD36, CEBPB, BGLAP, BMP7, ALPP, TNFRSF11B
3phosphorus32 9.7VDR, B2M, SLC34A1, SLPI, ACP5, PTH1R
4glucose32 9.6GAST, RUNX2, PTH, CASR, FGFR1, BMP7
5alendronate32 9 9 11.4RUNX2, SLPI, PTH, TNFRSF11B, CALCA, ALPP
6pamidronate32 9 9 11.3PTH, TNFRSF11B, CALCA, CASR, ALPP, IL6
7pyridinoline32 9.3CD36, PAX5, BGLAP, IGFBP3, IGF1, ACP5
8estradiol32 9 18 9 12.2SLPI, PRL, TNFRSF11B, IGFBP1, CCND1, CDKN1B
9deoxypyridinoline32 9.2ACP5, PTH, TNFRSF11B, ALPP, IGF1, IGFBP3
10aspartate32 9.0RET, CST3, CXADR, ACP5, CTNNB1, TNFRSF11B
11cysteine32 8.9CTNNB1, CASR, CARS, ALPP, ALB, IGFBP3
12procollagen32 8.9ACP5, PTH, TNFRSF11B, GHR, ALPP, IGF1
13ascorbic acid32 18 9.7BMP7, VDR, BGLAP, GAST, EPO, RUNX2
14pge232 8.7BMP7, VIP, FGF2, CCK, GAST, RUNX2
151,25 dihydroxy vitamin d332 8.6TNFRSF11B, CALCA, CASR, ALPP, IGF1, IGFBP3
16vitamin b1232 8.5ALB, IGF1, IGFBP3, GPT, B2M, ALPP
17dihydrotestosterone32 9 18 9 11.2PRL, TGFA, TNFRSF11B, GHR, IGF1, IGFBP3
18cyclosporin a32 42 9.1SLPI, NPPA, CST3, TF, TGFA, TTR
19gnrh32 8.0TGFA, CTNNB1, GHRL, GHR, IGF1, IGFBP3
20ly29400232 8.0TNFRSF11B, CCND1, IL6, FGF2, CDKN1B, RET
21creatinine32 7.8PDLIM3, SPG7, PTH, TNFRSF11B, GHRL, GHR
22adenylate32 7.6IGFBP3, GPT, CCK, CCND1, FGFR1, CEBPB
23tgf beta132 7.6BMP7, CDKN1A, CD36, RUNX2, SLPI, TGFA
24steroid32 7.6SLPI, CST3, CXADR, PRL, TGFA, NR1I3
25calcium32 9 18 9 10.5RUNX2, SLC20A1, SLC34A1, SLPI, CST3, CXADR
26ribonucleic acid32 7.4RUNX2, CXADR, PRL, TGFA, NR1I3, PTH1R
27vitamin a32 9 18 9 10.4CST3, RET, TF, TTR, CTNNB1, GHR
28octreotide32 42 9 9 10.3GHRL, GHR, CALCA, IGF1, IGFBP3, IGFBP1
29glutamine32 7.3GAST, CST3, TF, TGFA, TTR, CTNNB1
30acth32 7.2GAST, PRL, GHRL, GHR, CASR, IGF1
31glutamate32 7.1SLC6A11, CEBPB, VDR, VIP, GC, CDKN1B
32arginine32 7.0GHR, CASR, ALPP, IGFBP1, GPT, CCK
33sb 20358032 42 7.9RUNX2, EGFR, CTNNB1, TNFRSF11B, ALPP, IGF1
34norepinephrine32 9 18 9 9.6IL6, INS, CHGA, VIP, CCK, IGFBP1
35lactate32 6.5TF, VIP, CHGA, B2M, TGFA, TTR
36tamoxifen32 34 9 9 9.3PTH, TNFRSF11B, GHR, ALPP, IGF1, IGFBP3
37paraffin32 6.3ALPP, CCND1, FGF2, CDKN1B, CD36, CDKN1A
38thyroxine32 18 7.1IGFBP1, GPT, FGF2, INS, B2M, BGLAP
39genistein32 9 18 9 8.9IGFBP1, CCND1, IL6, FGFR1, FGF2, CDKN1B
40cholesterol32 9 18 9 8.8SLPI, CST3, TF, TTR, NR1I3, CHGA
41retinoic acid32 42 18 7.7IGFBP3, RET, GC, VDR, IGFBP1, CCK
42calcitriol32 42 9 18 9 9.7GAST, EPO, SLC34A1, SLPI, CXADR, TGFA
43cycloheximide32 5.6IGFBP3, IGFBP1, CCND1, IL6, FGF2, CDKN1B
44vegf32 5.4GAST, EPO, RUNX2, SLPI, NPPA, CST3
45testosterone32 9 18 9 8.2IGFBP3, IGFBP1, CCK, CCND1, FGFR1, CDKN1B
46vitamin d32 4.8BMP7, VDR, GC, GAST, EPO, RUNX2
47dexamethasone32 42 34 9 9 8.6GHRL, GHR, ALPP, IGF1, IGFBP3, IGFBP1
48alanine32 4.3ALPP, RET, ALB, IGFBP3, IGFBP1, GPT
49tyrosine32 3.6TGFA, MEN1, FGFR1, FGF23, FGF2, INS
50serine32 3.1CST3, CXADR, TGFA, TTR, EGFR, NR1I3

GO Terms for genes affiliated with Secondary Hyperparathyroidism

about this section
Sources:
12Gene Ontology
See all sources

Cellular components related to secondary hyperparathyroidism according to GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:0056154.7EPO, CCK, IL6, FGF23, FGF2, INS
2extracellular regionGO:0055764.1GAST, EPO, SLPI, NPPA, CCK, IL6

Biological processes related to secondary hyperparathyroidism according to GeneDecks:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathwayGO:09008010.4KL, FGF23, FGFR1
2bone resorptionGO:04545310.4ACP5, CTNNB1, PTH1R, PTH
3osteoblast developmentGO:00207610.2BGLAP, MEN1, PTH1R
4response to cadmium ionGO:04668610.2SLC34A1, CTNNB1, B2M
5agingGO:00756810.2EPO, PTH1R, CALCA, VDR, KL
6negative regulation of phosphorylationGO:04232610.2CDKN1B, CDKN2C, CDKN1A, BMP7
7response to magnesium ionGO:03202610.1CCND1, TNFRSF11B, SLC34A1
8response to estrogen stimulusGO:0436279.8EPO, TNFRSF11B, GHRL, CCND1, BGLAP
9skeletal system developmentGO:0015019.8PTH1R, PTH, TNFRSF11B, IGF1, FGFR1, BGLAP
10positive regulation of tyrosine phosphorylation of Stat5 proteinGO:0425239.8EPO, GHR, IGF1
11lactationGO:0075959.7GC, VDR, CCND1, PRL
12G1 phase of mitotic cell cycleGO:0000809.7CCND1, CDKN1B, CDKN2C, CDKN1A
13negative regulation of cyclin-dependent protein kinase activityGO:0457369.6MEN1, CDKN1B, CDKN1A
14fibroblast growth factor receptor signaling pathwayGO:0085439.5FGFR1, FGF23, FGF2, CDKN1B, KL
15negative regulation of cell growthGO:0303089.5NPPA, FGF2, CDKN1B, CDKN2C, CDKN1A
16positive regulation of glycogen biosynthetic processGO:0457259.5INS, IGF1, PTH
17negative regulation of transcription, DNA-dependentGO:0458929.4RUNX2, CTNNB1, CALCA, MEN1, FGF2, CDKN1B
18positive regulation of osteoblast differentiationGO:0456699.3IGF1, IL6, MEN1, FGF2, CEBPB, BMP7
19response to drugGO:0424939.3SLC6A11, TGFA, CTNNB1, TNFRSF11B, CCND1, CDKN1A
20insulin receptor signaling pathwayGO:0082869.2IGFBP1, FGFR1, FGF23, FGF2, INS, KL
21G-protein coupled receptor signaling pathwayGO:0071869.1GAST, PTH1R, PTH, GHRL, CASR, INS
22positive regulation of DNA replicationGO:0457408.9EPO, EGFR, IGF1, INS
23positive regulation of transcription from RNA polymerase II promoterGO:0459448.6PTH, IGF1, IL6, MEN1, FGF2, CDC73
24MAPK cascadeGO:0001658.5TGFA, EGFR, MEN1, FGFR1, INS, RET
25positive regulation of peptidyl-tyrosine phosphorylationGO:0507318.4GHR, IGF1, CCK, IL6, INS, CD36
26positive regulation of transcription, DNA-dependentGO:0458938.3EPO, RUNX2, CTNNB1, HNRNPD, IGF1, IL6
27positive regulation of MAPK cascadeGO:0434108.2IGF1, IGFBP3, IL6, FGFR1, INS, CD36
28signal transductionGO:0071658.2NR1I3, EGFR, SLC20A1, EPO, GAST, TNFRSF11B
29negative regulation of cell proliferationGO:0082858.2VDR, CTNNB1, PTH1R, IGF1, IGFBP3, IL6
30negative regulation of apoptotic processGO:0430667.7EPO, EGFR, GHRL, ALB, IL6, FGFR1
31positive regulation of cell proliferationGO:0082847.3IGF1, PTH1R, EGFR, EPO, CCK, IL6

Molecular functions related to secondary hyperparathyroidism according to GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1vitamin D bindingGO:00549910.3VDR, GC, KL
2fibroblast growth factor bindingGO:0171349.9KL, FGF2, FGFR1
3cyclin-dependent protein kinase inhibitor activityGO:0048619.8CDKN1B, CDKN2C, CDKN1A
4growth factor activityGO:0080838.9BMP7, FGF2, FGF23, IL6, IGF1, TGFA
5protein phosphatase bindingGO:0199038.9CDKN1B, GHR, CTNNB1, EGFR
6hormone activityGO:0051797.7KL, GAST, EPO, NPPA, PRL, TTR
7protein bindingGO:0055153.6EGFR, CTNNB1, SPG7, GHR, HNRNPD, CALCA

Sources for Secondary Hyperparathyroidism

about this section
2CDC
11FMA
18HMDB
19ICD9CM
20KEGG
24MeSH
25MGI
27NCIt
28NDF-RT
31NINDS
32Novoseek
33OMIM
35PubMed
36QIAGEN
43UMLS
Browse MalaCards: 1-9 | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z